<DOC>
	<DOCNO>NCT02184533</DOCNO>
	<brief_summary>The purpose study determine maximum-tolerated dose ( MTD ) sodium selenite administer combination radiation therapy subject metastatic cancer base safety tolerability .</brief_summary>
	<brief_title>Sodium Selenite Radiation Therapy Treating Patients With Metastatic Cancer</brief_title>
	<detailed_description>Primary Objectives : - To determine maximum tolerate dose ( MTD ) sodium selenite give combination palliative radiation therapy - To assess safety tolerability combination sodium selenite palliative radiation therapy metastatic cancer Secondary Objectives : - To assess pharmacokinetics sodium selenite - To evaluate anti tumor activity sodium selenite palliative radiation therapy give combination OUTLINE : Patients receive sodium selenite orally ( PO ) 2 hour daily radiation therapy treatment . Treatment continue duration course radiation therapy absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 2 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Selenious Acid</mesh_term>
	<mesh_term>Sodium Selenite</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm adenocarcinoma prostate prostate biopsy prostatectomy specimen ( primary site ) , histological confirmation adenocarcinoma /carcinoma metastatic site disease set elevate PSA image consistent metastatic prostate cancer , history prostate cancer document metastasis , histologically confirm solid tumor malignancy pathological confirmation metastasis Metastatic cancer require palliative radiation therapy For patient metastatic prostate cancer , PSA ≥ 2 ng/mL , except patient recently start androgen deprivation therapy PSA &lt; 2 ng/mL Age ≥ 18 year Life expectancy great 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Karnofsky performance status ≥ 80 % QT interval correct use Fridericia 's method ( QTcF ) &lt; 460 msec ( see Appendix C Fredericia 's criterion ) . Ability understand willingness sign write informed consent document Exclusion criterion : Inadequate organ function , evidence follow screening : Absolute neutrophil count ( ANC ) &lt; 1500/µL Platelet count ≤ 100 x 109/L Serum creatinine &gt; 2.0 mg/dL Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) AST , and/or ALT &gt; 2 x ULN Hemoglobin &lt; 9 g/dL Men reproductive potential agree use accept effective method contraception study treatment period least 3 month completion study treatment History malignancy within 5 year prior Day 1 except tumor opinion investigator negligible risk metastasis death , ( exclusively ) adequately control basal cell carcinoma , squamous cell carcinoma skin , early stage bladder cancer Current , recent ( within 4 week first treatment study ) chemotherapy experimental drug therapy , plan participation experimental drug study Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant vascular disease ( e.g . aortic aneurysm , aortic dissection ) , symptomatic peripheral vascular disease , psychiatric illness/social situation would limit compliance study requirement History myocardial infarction unstable angina within 6 month prior study enrollment History stroke transient ischemic attack within 6 month prior study enrollment The subject know positive human immunodeficiency virus ( HIV ) receive antiretroviral therapy . Subjects know HIV positive require antiretroviral therapy eligible meet entry criterion . Women pregnant breastfeeding Inability comply study and/or follow procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>